Aimovig (erenumab) vs Emgality (galcanezumab)
Aimovig (erenumab) vs Emgality (galcanezumab)
Aimovig (erenumab) and Emgality (galcanezumab) are both monoclonal antibodies used for the preventive treatment of migraine in adults, but they target different proteins involved in the pathophysiology of migraine. Aimovig blocks the calcitonin gene-related peptide receptor (CGRP-R), thereby preventing the binding of the CGRP peptide, which is implicated in migraine development. Emgality, on the other hand, binds directly to the CGRP ligand and prevents it from interacting with its receptor, potentially offering a similar therapeutic effect with a different mechanism of action. When deciding between the two, it is important to discuss with a healthcare provider the individual's medical history, potential side effects, and how the mode of administration of each drug aligns with their preferences and lifestyle.
Difference between Aimovig and Emgality
| Metric | Aimovig (erenumab) | Emgality (galcanezumab) |
|---|---|---|
| Generic name | Erenumab | Galcanezumab |
| Indications | Preventive treatment of migraine in adults | Preventive treatment of migraine in adults and treatment of episodic cluster headache in adults |
| Mechanism of action | Calcitonin gene-related peptide (CGRP) receptor antagonist | Calcitonin gene-related peptide (CGRP) ligand antagonist |
| Brand names | Aimovig | Emgality |
| Administrative route | Subcutaneous injection | Subcutaneous injection |
| Side effects | Injection site reactions, constipation, cramps, muscle spasms | Injection site reactions, pain, and reactions, upper respiratory tract infections |
| Contraindications | Known hypersensitivity to erenumab or any of its excipients | Known hypersensitivity to galcanezumab or any of its excipients |
| Drug class | Monoclonal antibody | Monoclonal antibody |
| Manufacturer | Amgen Inc. | Eli Lilly and Company |
Efficacy
Efficacy of Aimovig (Erenumab) for Migraine
Aimovig (erenumab) is a monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor, which plays a significant role in migraine pathophysiology. Clinical trials have demonstrated that Aimovig is effective in reducing the frequency of migraine days in individuals with episodic and chronic migraine. In pivotal studies, patients treated with Aimovig reported experiencing, on average, two to three fewer migraine days per month compared to placebo. Additionally, a subset of patients experienced a reduction of 50% or more in the number of migraine days, which suggests a significant improvement in the quality of life for these individuals.
Efficacy of Emgality (Galcanezumab) for Migraine
Emgality (galcanezumab) is another monoclonal antibody that targets CGRP, a neuropeptide involved in migraine attacks. Clinical trials have shown that Emgality is effective in reducing monthly migraine days in patients with episodic and chronic migraine. Patients receiving Emgality reported a reduction of migraine days that was statistically significant compared to placebo. Similar to Aimovig, a considerable proportion of patients treated with Emgality experienced a 50% or greater reduction in monthly migraine days, indicating a substantial therapeutic benefit for those suffering from migraines.
Comparison of Efficacy
When comparing the efficacy of Aimovig and Emgality, both medications appear to have similar effects on reducing the frequency of migraine days. The choice between these medications may be influenced by factors such as individual patient response, side effect profile, dosing schedule, and insurance coverage. Both Aimovig and Emgality are part of a class of drugs known as CGRP inhibitors, which have provided a new avenue for the preventive treatment of migraine, offering hope to patients who have not responded well to other treatments.
Conclusion
In conclusion, both Aimovig and Emgality have been shown to be effective in reducing the frequency of migraine days in patients with episodic and chronic migraine. They represent a significant advancement in migraine prophylaxis due to their targeted mechanism of action. The introduction of these CGRP inhibitors has expanded the options available to healthcare providers and patients for the management of migraine, potentially improving the quality of life for those affected by this debilitating condition.
Regulatory Agency Approvals
Aimovig
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
-
Therapeutic Goods Administration (TGA), Australia
-
Swissmedic (CH)
-
Medsafe (NZ)
Emgality
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
Access Aimovig or Emgality today
If Aimovig or Emgality are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us